Loading…
US President Donald Trump announced on 21 July 2026 a phased tariff plan on imported generic medicines, rising from 0% (from 1 August 2026, for two years) to 100% and eventually 200% by August 2029, using Section 232 of the Trade Expansion Act, 1962.
Branded/patented medicines already faced a separate 100% tariff; this new plan specifically targets generic drugs, which had previously faced no tariff.
India, whose pharma exports to the US were worth USD 9.7 billion in FY 2024-25 (~38% of India's total USD 25.8 billion global pharma exports), is significantly exposed given a February 2026 India-US trade understanding on pharmaceuticals.
The stated goal is to push generic drug manufacturing back onto US soil, reducing import dependence.
Generic medicines contain the same active ingredients, dosage strength and route of administration as branded drugs, at 80-85% lower cost, since generic makers don't bear original R&D/discovery costs. This new tariff targets generics specifically, distinct from the existing 100% tariff already applied to branded/patented medicines.
Simple Analogy: Like a store-brand product versus a name-brand one — same ingredients and effect, sold cheaper because the store didn't have to invent the recipe.
0% tariff on imported generic drugs begins (2-year window)
Tariff rises to 100%
Tariff rises to 200%
GS Paper III - Indian Economy (International trade, pharma exports) & GS Paper II (India-US relations)
US law allowing the President to impose trade restrictions on imports deemed a threat to national security